Neoantigen × AI
Daily research signal
№51Brief

Moderna, Merck neoantigen vaccine hits Phase 3 melanoma endpoint

The signal today is the first positive Phase 3 for a personalized neoantigen vaccine: Moderna and Merck's mRNA shot plus Keytruda met its primary endpoint in resected high-risk/advanced melanoma, moving the category from proof-of-concept toward regulatory filing and repricing both stocks sharply.CNBCOncology News Central

The rest of the tape is early-stage — NantBioScience's YENEO-001 draws analyst coverage in Phase I TNBC, and a pipeline profile highlights its yeast/peptide-based neoantigen approach.Pharmaceutical TechnologyPatsnap Synapse Net read: the field now spans a validated mRNA personalization platform at scale plus earlier, delivery-diverse entrants.

1new story3 in context
ClinicalyesterdayNew

Personalized Cancer Vaccine Shows Promise in Melanoma Trial - Oncology News Central

Personalized Cancer Vaccine Shows Promise in Melanoma Trial Oncology News Central

news · yesterday · Oncology News Central

03

Relevant work from earlier we're still surfacing — not today's news.